{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:47:13Z","timestamp":1761490033266,"version":"3.41.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.lpm.2016.06.020","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T05:22:04Z","timestamp":1469769724000},"page":"e289-e298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"P2","title":["Platelet concentrates: Balancing between efficacy and safety?"],"prefix":"10.1016","volume":"45","author":[{"given":"Miguel","family":"Lozano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Cid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2016.06.020_bib0355","series-title":"Platelet transfusion therapy","article-title":"Epidemiology of platelet transfusion","author":"Sweeney","year":"2013"},{"key":"10.1016\/j.lpm.2016.06.020_bib0360","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/trf.12791","article-title":"Transfusion-related adverse events in the Platelet Dose study","volume":"55","author":"Kaufman","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0365","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fimmu.2015.00028","article-title":"Platelet transfusion\u00a0\u2013\u00a0the new immunology of an old therapy","volume":"6","author":"Stolla","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.lpm.2016.06.020_bib0370","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.1939.02800500033008","article-title":"Preservation of stored blood with sulfanilamide","volume":"113","author":"Novak","year":"1939","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.lpm.2016.06.020_bib0375","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V60.1.194.194","article-title":"Improved storage of platelets for transfusion in a new container","volume":"60","author":"Murphy","year":"1982","journal-title":"Blood"},{"year":"1986","series-title":"Reduction of the maximum platelet storage period to 5\u00a0days in an approved container","key":"10.1016\/j.lpm.2016.06.020_bib0380"},{"key":"10.1016\/j.lpm.2016.06.020_bib0385","series-title":"Blood component preparation: from benchtop to bedside","first-page":"247","article-title":"Pathogen inactivation technologies for blood components","author":"Lozano","year":"2011"},{"key":"10.1016\/j.lpm.2016.06.020_bib0390","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJM199712253372601","article-title":"Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group","volume":"337","author":"The Trial to Reduce Alloimmunization to Platlets Study Group","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2016.06.020_bib0395","series-title":"Platelet transfusion therapy","article-title":"Bacterial contamination of platelet products","author":"Benjamin","year":"2013"},{"key":"10.1016\/j.lpm.2016.06.020_bib0400","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/asheducation-2003.1.575","article-title":"Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine","author":"Hillyer","year":"2003","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.lpm.2016.06.020_bib0405","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1086\/529143","article-title":"Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets","volume":"46","author":"Jacobs","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lpm.2016.06.020_bib0410","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/trf.12883","article-title":"Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French National Hemovigilance Network from 2000\u00a0to 2008","volume":"55","author":"Lafeuillade","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0415","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/j.1537-2995.2011.03554.x","article-title":"Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission","volume":"52","author":"Benjamin","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0420","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1056\/NEJMc1507761","article-title":"The safety of the blood supply\u00a0\u2013\u00a0time to raise the bar","volume":"373","author":"Snyder","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2016.06.020_bib0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/1560-7917.ES2014.19.14.20761","article-title":"Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia. November 2013\u00a0to February 2014","volume":"19","author":"Musso","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.lpm.2016.06.020_bib0430","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/vox.12098","article-title":"Bacterial contamination in platelet concentrates","volume":"106","author":"Pietersz","year":"2014","journal-title":"Vox Sang"},{"key":"10.1016\/j.lpm.2016.06.020_bib0435","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.tmrv.2014.01.001","article-title":"The international experience of bacterial screen testing of platelet components with an automated microbial detection system: a need for consensus testing and reporting guidelines","volume":"28","author":"Benjamin","year":"2014","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.lpm.2016.06.020_bib0440","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1537-2995.2007.01248.x","article-title":"Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004\u20132006)","volume":"47","author":"Eder","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0445","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1423-0410.2008.01051.x","article-title":"Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety","volume":"95","author":"Murphy","year":"2008","journal-title":"Vox Sang"},{"key":"10.1016\/j.lpm.2016.06.020_bib0450","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1537-2995.2009.02460.x","article-title":"Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results","volume":"50","author":"Dumont","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0455","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-3148.2010.01037.x","article-title":"Screening of platelets for bacterial contamination at the Welsh Blood Service","volume":"21","author":"Pearce","year":"2011","journal-title":"Transfus Med"},{"key":"10.1016\/j.lpm.2016.06.020_bib0460","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1423-0410.2011.01485.x","article-title":"Extension of platelet shelf life from 4\u00a0to 5\u00a0days by implementation of a new screening strategy in Germany","volume":"101","author":"Sireis","year":"2011","journal-title":"Vox Sang"},{"key":"10.1016\/j.lpm.2016.06.020_bib0465","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1537-2995.2012.03818.x","article-title":"Routine use of a rapid test to detect bacteria at the time of issue for nonleukoreduced, whole blood-derived platelets","volume":"53","author":"Harm","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0470","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1111\/trf.12083","article-title":"Routine bacterial screening of apheresis platelets on Day 4\u00a0using a rapid test: a 4-year single-center experience","volume":"53","author":"Dunbar","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0475","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1046\/j.1537-2995.1999.39111160.x","article-title":"The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1","volume":"39","author":"Tabor","year":"1999","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0480","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1537-2995.1997.37497265344.x","article-title":"Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light","volume":"37","author":"Lin","year":"1997","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0485","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.0041-1132.2005.04316.x","article-title":"Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light","volume":"45","author":"Lin","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0490","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/j.1537-2995.2006.00867.x","article-title":"Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function","volume":"46","author":"Singh","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0495","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1537-2995.2007.01133.x","article-title":"The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy coat platelets","volume":"47","author":"Castro","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0500","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood.V91.6.2180","article-title":"Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA","volume":"91","author":"Grass","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2016.06.020_bib0505","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/vox.12158","article-title":"Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma","volume":"107","author":"Kwon","year":"2014","journal-title":"Vox Sang"},{"key":"10.1016\/j.lpm.2016.06.020_bib0510","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood-2013-09-524348","article-title":"Hepatitis E transmission by transfusion of Intercept blood system-treated plasma","volume":"123","author":"Hauser","year":"2014","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.lpm.2016.06.020_bib0515","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1423-0410.2000.tb00065.x","article-title":"The use of riboflavin for the inactivation of pathogens in blood products","volume":"78","author":"Goodrich","year":"2000","journal-title":"Vox Sang"},{"key":"10.1016\/j.lpm.2016.06.020_bib0520","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1537-2995.2005.04350.x","article-title":"Effects of a new pathogen reduction technology (Mirasol PRT) on functional aspects of platelet concentrates","volume":"45","author":"Perez-Pujol","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0525","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1537-2995.2004.03355.x","article-title":"Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light","volume":"44","author":"Ruane","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0530","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.transci.2007.07.002","article-title":"Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light","volume":"37","author":"Cardo","year":"2007","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.lpm.2016.06.020_bib0535","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1537-2995.2011.03285.x","article-title":"Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood","volume":"52","author":"Tonnetti","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0540","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1111\/trf.12079","article-title":"Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light","volume":"53","author":"Keil","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0545","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/j.1537-2995.2006.00939.x","article-title":"Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-\/-gamma c-\/- double knockout mice","volume":"46","author":"Fast","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0550","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1111\/j.1537-2995.2010.02714.x","article-title":"White blood cell inactivation after treatment with riboflavin and ultraviolet light","volume":"50","author":"Marschner","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0555","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000323845","article-title":"UVC irradiation for pathogen reduction of platelet concentrates and plasma","volume":"38","author":"Seltsam","year":"2011","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.lpm.2016.06.020_bib0560","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1537-2995.2007.01524.x","article-title":"Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates","volume":"48","author":"Terpstra","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0565","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1111\/j.1537-2995.2009.02334.x","article-title":"A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light","volume":"49","author":"Mohr","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0570","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/trf.12836","article-title":"Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products","volume":"55","author":"Pohler","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0575","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1423-0410.2000.7940206.x","article-title":"Functional characteristics of S-59\u00a0photochemically treated platelet concentrates derived from buffy coats","volume":"79","author":"van Rhenen","year":"2000","journal-title":"Vox Sang"},{"key":"10.1016\/j.lpm.2016.06.020_bib0580","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1537-2995.2003.00590.x","article-title":"Functional characteristics of buffy coat PLTs photochemically treated with amotosalen HCl for pathogen inactivation","volume":"44","author":"Picker","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0585","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1537-2995.2007.01169.x","article-title":"Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7\u00a0days: assessment of hemostatic function under flow conditions","volume":"47","author":"Lozano","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0590","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/j.0041-1132.2004.04145.x","article-title":"Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light","volume":"44","author":"Snyder","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0595","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1537-2995.2006.00791.x","article-title":"Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia","volume":"46","author":"Slichter","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0600","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1423-0410.2009.01193.x","article-title":"Pathogen reduction technology (Mirasol) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS","volume":"97","author":"Janetzko","year":"2009","journal-title":"Vox Sang"},{"key":"10.1016\/j.lpm.2016.06.020_bib0605","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/trf.13033","article-title":"Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?","volume":"55","author":"van der Meer","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0610","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1537-2995.2010.02914.x","article-title":"Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function","volume":"51","author":"Galan","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0615","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1537-2995.2005.00202.x","article-title":"Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction","volume":"45","author":"AuBuchon","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0620","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.transci.2012.01.008","article-title":"Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system\u00a0\u2013\u00a0an update","volume":"46","author":"Seghatchian","year":"2012","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.lpm.2016.06.020_bib0625","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1537-2995.2012.03854.x","article-title":"Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets","volume":"53","author":"Bashir","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0630","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood-2002-03-0932","article-title":"Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial","volume":"101","author":"van Rhenen","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2016.06.020_bib0635","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2003-12-4443","article-title":"Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial","volume":"104","author":"McCullough","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2016.06.020_bib0640","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1537-2995.2005.00639.x","article-title":"Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial","volume":"45","author":"Snyder","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0645","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/j.1537-2995.2005.00550.x","article-title":"Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set","volume":"45","author":"Janetzko","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0650","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2010.08227.x","article-title":"Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction","volume":"150","author":"Kerkhoffs","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.lpm.2016.06.020_bib0655","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2016.06.020_bib0660","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2141.2011.08635.x","article-title":"A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6\u00a0or 7\u00a0d prior to transfusion","volume":"153","author":"Lozano","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.lpm.2016.06.020_bib0665","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1537-2995.2010.02925.x","article-title":"Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets","volume":"51","author":"Vamvakas","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0670","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1423-0410.2011.01555.x","article-title":"Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system","volume":"102","author":"Vamvakas","year":"2012","journal-title":"Vox Sang"},{"key":"10.1016\/j.lpm.2016.06.020_bib0675","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1423-0410.2012.01614.x","article-title":"Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials","volume":"103","author":"Cid","year":"2012","journal-title":"Vox Sang"},{"key":"10.1016\/j.lpm.2016.06.020_bib0680","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/j.1537-2995.2009.02151.x","article-title":"Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use","volume":"49","author":"Osselaer","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0685","series-title":"Platelet transfusion therapy","article-title":"Pathogen inactivation of platelets","author":"Cazenave","year":"2013"},{"key":"10.1016\/j.lpm.2016.06.020_bib0690","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1537-2995.2010.02694.x","article-title":"A randomized controlled clinical trial evaluating the performance and safety of platelets treated with Mirasol(R) pathogen reduction technology","volume":"50","author":"The Mirasol clinical evaluation study group","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0695","first-page":"4A","article-title":"Clinical efficacy and safety of platelets in additive solution treated with two commercial pathogen reduction technologies","volume":"55","author":"Rebulla","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2016.06.020_bib0700","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/vox.12247","article-title":"Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction\u00a0\u2013\u00a0a phase I clinical trial","volume":"109","author":"Thiele","year":"2015","journal-title":"Vox Sang"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498216301695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498216301695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T08:50:22Z","timestamp":1749027022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498216301695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":70,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0755498216301695"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2016.06.020","relation":{},"ISSN":["0755-4982"],"issn-type":[{"type":"print","value":"0755-4982"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet concentrates: Balancing between efficacy and safety?","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.06.021","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.06.024","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.06.023","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.06.016","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.06.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.06.019","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.06.025","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.06.018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.06.017","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.06.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}